Menu
Search
|

Menu

Close
X

Amgen Inc AMGN.OQ (NASDAQ Stock Exchange Global Select Market)

195.04 USD
-- (--)
As of Sep 18
Previous Close 195.04
Open --
Volume --
3m Avg Volume 1,154,849
Today’s High --
Today’s Low --
52 Week High 211.89
52 Week Low 166.30
Shares Outstanding (mil) 609.94
Market Capitalization (mil) 107,397.50
Forward P/E 14.05
Dividend (Yield %) 1.45 ( 3.29 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 24 analysts

KEY STATS

Revenue (mm, USD)
FY19
5,557
FY18
23,747
FY17
22,849
FY16
22,991
EPS (USD)
FY19
3.182
FY18
12.601
FY17
10.999
FY16
10.260
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
14.05
33.85
Price to Sales (TTM)
vs sector
4.52
7.90
Price to Book (MRQ)
vs sector
9.99
4.38
Price to Cash Flow (TTM)
vs sector
10.69
23.70
Total Debt to Equity (MRQ)
vs sector
304.87
17.64
LT Debt to Equity (MRQ)
vs sector
270.67
12.61
Return on Investment (TTM)
vs sector
14.42
12.69
Return on Equity (TTM)
vs sector
61.05
17.13

EXECUTIVE LEADERSHIP

Robert Bradway
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $1,566,000.00
Bonus: --
David Meline
Executive Vice President, Chief Financial Officer, Since 2014
Salary: $977,746.00
Bonus: --
Murdo Gordon
Executive Vice President of Global Commercial Operations, Since 2018
Salary: $330,769.00
Bonus: $2,000,000.00
David Reese
Executive Vice President - Research and Development, Since 2018
Salary: $697,500.00
Bonus: $300,000.00
Esteban Santos
Executive Vice President, Operations, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Amgen Center Dr
THOUSAND OAKS   CA   91320-1730

Phone: +1805.4471000

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

SPONSORED STORIES